非アルコール性脂肪肝炎バイオマーカーの市場規模、シェア、成長分析：タイプ別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

非アルコール性脂肪肝炎バイオマーカーの世界市場規模は2023年に10億1,000万米ドルと評価され、2024年の13億米ドルから2032年には97億8,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは28.7％で成長する見通しです。

世界の非アルコール性脂肪肝炎（NASH）バイオマーカー市場は、肥満や代謝障害に関連した慢性肝疾患であるNASHの有病率の上昇に後押しされ、大幅な成長が見込まれています。この罹患率の急増は、早期診断、疾患進行のモニタリング、治療反応の評価のための信頼性の高いバイオマーカーの必要性を強調しています。バイオマーカーは、リスクのある人を特定し、NASHと他の肝疾患を区別し、重症度を評価するために不可欠です。この市場は、研究の進歩と新規の非侵襲的診断ツールの開発によってさらに強化されています。効果的な診断とモニタリングのソリューションに対する需要が高まる中、市場関係者には、NASH管理における重要なニーズを満たす、最先端のバイオマーカーに基づく製品を革新的に導入する十分な機会があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

非アルコール性脂肪肝炎バイオマーカー市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 肝線維症バイオマーカー
• 血清バイオマーカー
• 酸化ストレスバイオマーカー
• アポトーシスバイオマーカー
• その他

非アルコール性脂肪肝炎バイオマーカー市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 調査機関と学術機関
• 診断センター
• 製薬会社とCRO
• 病院と診療所
• その他

非アルコール性脂肪肝炎バイオマーカー市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Genfit SA（France）
• Gilead Sciences, Inc.（United States）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（United States）
• Abbott Laboratories（United States）
• Prometheus Laboratories Inc.（United States）
• NGM Biopharmaceuticals, Inc.（United States）
• Metabolon, Inc.（United States）
• Perspectum Ltd（United Kingdom）
• Precision Medicine Group, Inc.（United States）
• Grifols, S.A.（Spain）
• Hologic, Inc.（United States）
• Quest Diagnostics Incorporated（United States）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Biopredictive（France）

結論と推奨事項

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.01 billion in 2023 and is poised to grow from USD 1.3 billion in 2024 to USD 9.78 billion by 2032, growing at a CAGR of 28.7% during the forecast period (2025-2032).

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is poised for substantial growth, fueled by the rising prevalence of NASH, a chronic liver condition linked to obesity and metabolic disorders. This surge in incidence underscores the need for reliable biomarkers for early diagnosis, monitoring disease progression, and evaluating therapeutic responses. Biomarkers are essential for identifying at-risk individuals, distinguishing NASH from other liver diseases, and assessing severity. The market is further bolstered by advancements in research and the development of novel, non-invasive diagnostic tools. As the demand for effective diagnostic and monitoring solutions grows, market players have ample opportunities to innovate and introduce cutting-edge biomarker-based products, fulfilling the critical needs in NASH management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Alcoholic Steatohepatitis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Segmental Analysis

Global Non-alcoholic SteatohepatitisbiomarkersMarket is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Alcoholic Steatohepatitis Biomarkers Market

A significant driver fueling the global Non-Alcoholic Steatohepatitis (NASH) biomarkers market is the alarming rise in NASH cases globally. This liver condition, characterized by excess fat buildup that leads to inflammation and liver damage, is increasingly prevalent due to factors such as obesity, sedentary lifestyles, and poor dietary choices. Consequently, there is a heightened demand for reliable biomarkers that can facilitate early diagnosis, monitor the progression of the disease, and evaluate treatment efficacy. The escalating awareness surrounding NASH and the necessity for improved diagnostic methods further amplify the need for effective biomarkers in this growing market.

Restraints in the Global Non-Alcoholic Steatohepatitis Biomarkers Market

A notable challenge facing the Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers market is the absence of standardized biomarkers coupled with regulatory hurdles. The intricate processes involved in developing and validating biomarkers for NASH diagnosis and monitoring create significant barriers. The lack of consensus regarding the selection and application of these biomarkers limits their adoption across the industry. Moreover, regulatory bodies enforce strict validation requirements that can be both time-consuming and costly for developers. These complexities hinder the commercialization and acceptance of NASH biomarkers in clinical settings. To overcome these challenges, further research, standardization, and expert regulatory guidance are essential for maximizing the efficacy of NASH biomarkers and enhancing patient care.

Market Trends of the Global Non-Alcoholic Steatohepatitis Biomarkers Market

The global Non-Alcoholic Steatohepatitis (NASH) biomarkers market is witnessing a significant trend towards the adoption of non-invasive diagnostic techniques, reflecting the growing emphasis on patient-centric healthcare. NASH, characterized by complex liver pathology, necessitates early and accurate diagnosis for optimal management. In this landscape, non-invasive biomarkers, including advanced blood-based assays and imaging methods, are emerging as preferred alternatives to traditional liver biopsies, offering enhanced patient comfort, cost-efficiency, and accessibility. This shift not only promises to improve patient outcomes through timely intervention but also facilitates smoother clinical trial processes. As the demand for reliable and convenient diagnostics increases, this trend is poised to accelerate the growth of the global NASH biomarkers market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hepatic Fibrosis Biomarkers
• Serum Biomarkers
• Oxidative Stress Biomarkers
• Apoptosis Biomarkers
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Research Institutes and Academics
• Diagnostic Centres
• Pharmaceutical Companies and CROs
• Hospitals and Clinics
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size & CAGR (2025-2032)

• North America (Type, End User)
  • US
  • Canada
• Europe (Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Genfit SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prometheus Laboratories Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolon, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perspectum Ltd (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision Medicine Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopredictive (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations